FindTrial
Sign In

Clinical and population characteristics of patients with primary Antiphospholipid syndrome (APS)

Clinical and epidemiologic aspects of thrombotic primary Antiphospholipid syndrome (APS) - APS-EPI Antiphospholipid syndrome epidemiology

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-9pm4r64
Enrollment
Unknown
Registered
2023-05-31
Start date
2022-09-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphospohlipid Syndrome

Interventions

This is a cross-sectional observational study with 100 adult patients diagnosed with primary antiphospholipid syndrome (APS) consecutively recruited at the antiphospholipid syndrome clinic at the Hosp
E05.318.372.500.875

Sponsors

Faculdade de Medicina da Universidade de São Paulo
Lead Sponsor
University of Turin
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who meet the Sydney classification criteria for primary Antiphospholipid syndrome; age greater than 18 years old

Exclusion criteria

Exclusion criteria: Patients who do not have primary Antiphospholipid syndrome; patients who do not want to participate.

Design outcomes

Primary

MeasureTime frame
We expect that these results will permit a better categorization of primary antiphospholipide syndrome (PAPS) patients followed at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP) and a possible improvement in disease management. We are positive that epidemiological variables, that are still negligenced in APS, might play a role in disease outcome. These patients have a urgent need to have their quality of life measured and improved. Qualitative variables will be expressed as percentages and quantitative variables as means ± standard deviation (SD) or median (interquartile deviation), according to data distribution (normal or asymmetric). The normality of the data will be done by the Kolmogorov-Smirnov test and through graphical analysis. Categorical variables between the two groups will be compared using Fisher's test or chi-square, as appropriate. Continuous variables will be compared using Student's t test, Mann Whitney, ANOVA or Kruskal-Wallis, according to applicability. The tests will be two-tailed and validated with a statistical significance of 5%.—

Secondary

MeasureTime frame
Secondary outcomes are not expected.—

Countries

Brazil

Contacts

Public ContactDanieli Andrade

University of São Paulo

danieli.andrade@hc.fm.usp.br5511981628855

Outcome results

None listed

Source: REBEC (via WHO ICTRP)